Evidence map›Paper›PMID 41329952›Full record

ArticleJMIR research protocols2025

Newly Designed Optical Coherence Tomography Catheter for Optimizing Bladder Cancer Diagnosis and Treatment: Protocol for a Feasibility Study.

Marinka Jolinde Remmelink, Jakko A Nieuwenhuijzen, Daniel Martijn de Bruin, Jorg R Oddens

Registry-linked trialAbstract readClinical Trial Protocol
In one paragraph

Article in JMIR research protocols, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06679920 (IDEAL Phase II Study of a Newly Designed Optical Coherence Tomography Probe During Transurethral Resection for Optimizing Bladder Cancer Diagnosis and Treatment), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06679920 narecruitingnot on this map

IDEAL Phase II Study of a Newly Designed Optical Coherence Tomography Probe During Transurethral Resection for Optimizing Bladder Cancer Diagnosis and Treatment

TypeinterventionalSponsorAmsterdam UMCRan2024 to 2025Enrolled15ConditionsBladder CancerArmsOptical coherence tomography
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Marinka Jolinde RemmelinkDepartment of Urology, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0002-3118-5373
Jakko A NieuwenhuijzenCancer Center Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0002-8977-5501
Daniel Martijn de BruinDepartment of Biomedical Engineering and Physics, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0003-3047-3637
Jorg R OddensDepartment of Urology, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0002-6079-5613

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBladder cancer diagnosis relies on cystoscopy and transurethral resection of bladder tumor (TURBT) for histopathological evaluation, but this process is time consuming, costly, and subject to variability. Optical coherence tomography (OCT) offers real-time, high-resolution imaging as a potential alternative.

objectiveThis study primarily aims to assess the feasibility of capturing in vivo cross-sectional images of the bladder wall using a novel microelectromechanical systems (MEMS)-based OCT catheter. Secondary objectives include evaluating measurement duration, assessing tumor stage and grade from OCT images in comparison with histopathology, determining the catheter's ability to image resection beds, and comparing OCT-based tumor staging with white light cystoscopy assessments.

methodsThis single-center feasibility study at Amsterdam University Medical Center includes patients undergoing TURBT for suspected bladder tumors. Eligible patients must be aged 18 years or older, have at least 1 cystoscopically accessible tumor, and must be physically fit for TURBT. Exclusion criteria include pregnancy, tumors larger than 2 cm, more than 5 tumors, isolated flat lesions, or tumors solely at the bladder neck. The primary end point assesses the procedural feasibility of OCT imaging, while the secondary end points evaluate tumor staging, grading, and correlation with histopathology. Up to 25 patients will be enrolled, with feasibility achieved if diagnostic images are obtained in more than 60% of the cases. OCT imaging is performed before and after tumor resection, with histopathological results used for comparison. Patients will be monitored for adverse events for 4 weeks after the procedure, after which study participation ends.

resultsAs of November 2025, 16 participants have been enrolled, and 13 have successfully completed the study procedure. The projected end date of the study is November 2025, and results are expected to be published in March 2026.

conclusionsThis study is expected to provide key insights into the feasibility and clinical utility of the newly developed MEMS-based forward-looking OCT system for real-time bladder imaging during TURBT. This study will lay the groundwork for a larger trial to evaluate its diagnostic accuracy in staging and grading bladder cancer.

trial registrationClinicalTrials.gov NCT06679920; https://clinicaltrials.gov/study/NCT06679920. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/76644.

Indexed as

CathetersTomography, Optical CoherenceUrinary Bladder NeoplasmsClinical Trials as TopicCystoscopyFeasibility StudiesFemaleHumansMaleMulticenter Studies as TopicNeoplasm StagingUrinary Bladderbladder cancerdiagnosismicroelectromechanical systemsOCToptical coherence tomography

Identifiers

PMID41329952
PMCPMC12709158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.